Lanadelumab-flyo
Lanadelumab-flyo (pronounced as lana del' ue mab) is a monoclonal antibody used for the prevention of attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It is marketed under the brand name Takhzyro.
Etymology
The name "Lanadelumab-flyo" is derived from the International Nonproprietary Names (INN), where "Lana-" refers to the target (plasma kallikrein), "-lumab" is a suffix for monoclonal antibodies, and "-flyo" indicates the production method (recombinant DNA technology in Chinese hamster ovary cells).
Pharmacology
Lanadelumab-flyo is a fully human monoclonal antibody that binds to plasma kallikrein and inhibits its binding to high molecular weight kininogen (HMWK), thereby preventing the production of bradykinin, a peptide that causes blood vessels to dilate and become permeable, leading to the symptoms of HAE.
Usage
Lanadelumab-flyo is used for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It is administered by subcutaneous injection every 2 weeks.
Side Effects
Common side effects of Lanadelumab-flyo include injection site reactions, upper respiratory tract infection, headache, rash, muscle pain, dizziness, and diarrhea.
Related Terms
See Also
External links
- Medical encyclopedia article on Lanadelumab-flyo
- Wikipedia's article - Lanadelumab-flyo
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski